Total
0
Shares
Skin Elements (ASX:SKN) - Executive Chairman, Peter Malone
Executive Chairman, Peter Malone
Source: Business News
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Skin Elements’ (SKN) natural plant-based SE Formula has been proven 99.99 per cent effective against Feline coronavirus, a surrogate of COVID-19
  • The SE Formula is used within Skin Elements’ Invisi Shield Natural hand sanitiser
  • Skin Elements originally teamed up with Holista CollTech to create this formula
  • The testing showed that the formula kills 99.99 per cent of the virus after exposure and was accepted under European testing standards
  • Skin Elements shares are currently suspended, with last trade at eight cents per share

Skin Elements’ (SKN) natural plant-based SE Formula has been proven 99.99 per cent effective against Feline coronavirus, a surrogate of COVID-19. Both the Feline and COVID-19 coronaviruses are both members of the Coronaviridae family.

The testing shows the formula kills 99.99 per cent of the virus after exposure and was accepted under European testing standards. European testing standards are applied to ingredients used in the medical industry.

In April, the company finalised its Invisi Shield formula for the test. Skin Elements teamed up with Holista CollTech to create this plant-based formula.

The test was undertaken at Microbiological Solutions (MSL), a world-recognised, independent microbiology lavatory in the United Kingdom.

Skin Elements is a natural and organic skincare company that has international approvals to sell its Soléo Organics sunscreen and PapayaActivs therapeutic skincare products.

“These independent test results validate the efficacy of the SE Formula,” Executive Chairman Peter Malone said.

“Our goal is to now pursue the development of all-natural organic, alcohol-free active products that offer a natural solution for protection and control against germs compared to existing products,” he added.

Skin Elements shares are currently suspended, with last trade at eight cents per share.

SKN by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.